Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment

Basit Öğe Kaydı
dc.authoridARISOY, SEMA/0000-0003-2798-1884
dc.authorwosidARISOY, SEMA/V-1458-2017
dc.contributor.authorArisoy, Sema
dc.contributor.authorComoglu, Tansel
dc.date.accessioned2024-08-04T20:10:33Z
dc.date.available2024-08-04T20:10:33Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe severe acute respiratory syndrome-coronaviruse-2 (SARS-CoV-2) genome is packaged in a helical nucleocapsid surrounded by a lipid bilayer. The virus envelope contains at least three viral proteins called spike protein (S), membrane protein (M) and envelope protein (E). While M and E form the structure of the virus, S protein is the leading agent of the entry of viruses into the host. Angiotensin converting enzyme-2 (ACE-2) has been identified as a functional receptor for coronaviruses, including SARS-CoV and SARS-CoV-2. Viral fusion is the main step in the onset of SARS-CoV-2 infection. It is thought that drugs that prevent spike protein and ACE-2 fusion, drugs acting on the renin-angiotensin aldesterone system, and a high dose ACE-2 can act on this fusion mechanism and take part in COVID-19 treatment. In this context, especially nano-sized liposomal carriers attract attention due to their biocompatibility and cell-like structures in the treatment of infectious diseases. There are studies in which liposomes are also used as a secondary therapeutic to support traditional anti-infective drugs. In this review, therapeutic approaches that may reduce and treat the severity of the disease by preventing ACE-2 mediated entry of viruses are discussed.en_US
dc.identifier.doi10.14235/bas.galenos.2020.5080
dc.identifier.endpage125en_US
dc.identifier.issn2148-2373
dc.identifier.startpage117en_US
dc.identifier.trdizinid485124en_US
dc.identifier.urihttps://doi.org/10.14235/bas.galenos.2020.5080
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/485124
dc.identifier.urihttps://hdl.handle.net/11616/92864
dc.identifier.volume8en_US
dc.identifier.wosWOS:000613758900009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofBezmialem Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectliposomesen_US
dc.subjectCOVID-19 treatmenten_US
dc.titlePotential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatmenten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu